See more : JANU PUTRA SEJAHTERA TBK (AYAM.JK) Income Statement Analysis – Financial Results
Complete financial analysis of AN2 Therapeutics, Inc. (ANTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AN2 Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Centrais Elétricas de Santa Catarina S.A. (CLSC3.SA) Income Statement Analysis – Financial Results
- Emmis Corporation (EMMS) Income Statement Analysis – Financial Results
- Arkle Resources PLC (ARK.L) Income Statement Analysis – Financial Results
- Befesa S.A. (0RVK.L) Income Statement Analysis – Financial Results
- VITA 34 AG (VTIAF) Income Statement Analysis – Financial Results
AN2 Therapeutics, Inc. (ANTX)
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 77.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -77.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 54.87M | 29.51M | 16.91M | 6.02M | 4.89M |
| General & Administrative | 14.76M | 12.75M | 4.67M | 1.27M | 1.73M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 287.27K |
| SG&A | 14.76M | 12.75M | 4.67M | 1.27M | 289.00K |
| Other Expenses | 0.00 | -45.00K | -38.00K | -6.32M | 0.00 |
| Operating Expenses | 69.64M | 42.26M | 21.57M | 7.28M | 5.18M |
| Cost & Expenses | 69.64M | 42.26M | 21.57M | 7.28M | 5.18M |
| Interest Income | 0.00 | 1.35M | 69.00K | 3.00K | 0.00 |
| Interest Expense | 0.00 | 514.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 69.64M | 77.00K | 21.57M | 7.28M | 31.07M |
| EBITDA | 4.90M | -42.26M | 0.00 | -6.32M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -69.64M | -42.26M | -21.57M | -7.28M | -5.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.90M | 1.31M | 31.00K | -6.32M | -457.00K |
| Income Before Tax | -64.73M | -40.96M | -21.54M | -13.60M | -5.64M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 514.00K | -69.00K | -3.00K | -31.07K |
| Net Income | -64.73M | -41.47M | -21.47M | -13.60M | -5.64M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.74 | -2.14 | -1.15 | -0.73 | -0.30 |
| EPS Diluted | -2.74 | -2.14 | -1.15 | -0.73 | -0.30 |
| Weighted Avg Shares Out | 23.60M | 19.40M | 18.74M | 18.74M | 18.74M |
| Weighted Avg Shares Out (Dil) | 23.60M | 19.40M | 18.74M | 18.74M | 18.74M |
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the company's decision to voluntarily pause Phase 3 enrollment in the...
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the...
Recent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Why
AN2 Therapeutics, Inc. (ANTX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Why
AN2 Therapeutics, Inc. (ANTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
AN2 Therapeutics to Present at Upcoming Investor Conferences
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in...
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has received an exclusive license from the University of...
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced two oral presentations and three poster presentations at the Infectious Disease...
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has received a research grant from the Bill &...
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has commenced the Phase 3 part of its Phase...
Has AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year?
Here is how AN2 Therapeutics, Inc. (ANTX) and Artivion (AORT) have performed compared to their sector so far this year.
Source: https://incomestatements.info
Category: Stock Reports